Dr. Robert Haywood Hosea, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 701 Doctors Dr Ste K, Kinston, NC 28501 Phone: 252-523-0687 Fax: 252-523-0255 |
Dr. Charles Britton Beasley, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 701 Doctors Dr, Kinston, NC 28501 Phone: 252-523-0687 Fax: 252-523-0255 |
Dr. John David Cunningham Jr., MD, FACS Otolaryngology - Sleep Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 Doctors Dr Ste K, Kinston, NC 28501 Phone: 252-523-0687 Fax: 252-523-0255 |
Barbara Goheen, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 701 Doctors Dr Ste K, Kinston, NC 28501 Phone: 252-523-0687 Fax: 252-523-0255 |
Dr. Walter Roberts Sabiston, Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 701 Doctors Dr, Kinston, NC 28501 Phone: 252-523-0687 Fax: 252-523-0255 |
News Archive
Some 50 to 80 percent of cancer patients taking powerful chemotherapy drugs develop diarrhea, which can be severe and in some cases life-threatening.
Three cardiac surgeons from the Montreal Heart Institute, Dr. Yoan Lamarche, Dr. Ismail El-Hamamsy and Dr. Philippe Demers, are behind Aorta, a free app that provides specialists with patient-specific recommendations for aortic replacement surgery based on the latest scientific guidelines.
Approximately 1 in every 4 deaths in the United States is caused by heart disease, according to the Centers for Disease Control and Prevention.
Preliminary results from the first month of the UK Flusurvey run by scientists at the London School of Hygiene & Tropical Medicine suggest there is no evidence for "man flu" and reveal that reports of flu-like illness are highest among children.
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.
› Verified 1 days ago